EN DE
Watch Nasmed Ozel Saglik Hizmetleri Ticaret AS for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) fair value: what the stock is really worth

As of Oct 26, 2026: fair value (intrinsic value) of Nasmed Ozel Saglik Hizmetleri Ticaret AS stock TRY 1.00, price TRY 4.45, upside -77.5%, quality 33 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare · TR · ISIN TRENSMD00029

NO Nasmed Ozel Saglik Hizmetleri Ticaret AS logo Thin data Oct 26, 2026

Nasmed Ozel Saglik Hizmetleri Ticaret AS

EGEPO · IS

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 78% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +63.7 %/yr in TRY)
Loss over the last twelve months · -3.7% net margin (TTM) · fiscal year 2025 0.2%
Mixed vs. peers (6/12)
Fair value 1.00 TRY · Strongly overvalued (−77.5%)
Quality 33/100
Negative free cash flow
Narrow moat 19/100 · thin data
Thin data
Watch Nasmed Ozel Saglik Hizmetleri Ticaret AS for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

19.92 TRY 1.28 TRY Fair Value 1.00 TRY Sep 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 26, 2026.

How to read this chart

60‑month range 1.28 TRY – 19.92 TRY · fair‑value band 0.9400 TRY – 1.05 TRY · the 4.45 TRY price screens above the 1.00 TRY fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 26, 2026.

Follow Nasmed Ozel Saglik Hizmetleri Ticaret AS in your weekly email

Every Wednesday you see whether Nasmed Ozel Saglik Hizmetleri Ticaret AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi provides outpatient and inpatient examination, diagnosis, and treatment services to patients in Turkey.

Show moreShow less

The company constructs, renovates, establishes, purchases, and operates diagnostic and treatment facilities, laboratories, blood banks, rehabilitation centers, and other health-related institutions; and provides all health services, including preventive medicine.

It operates hospitals for emergency and emergency medical services, anesthesiology and reanimation, nutrition and dietetics, neurosurgery, pediatrics, dermatology, infectious diseases and clinical microbiology, aesthetics, plastic and reconstructive surgery, physical therapy and rehabilitation, gastroenterology, general surgery, interventional radiology, pulmonology, ophthalmology, internal medicine, obstetrics and gynecology, cardiovascular surgery, clinical biochemistry, neurology, orthopedics and traumatology, palliative care, psychiatry, psychology, radiology, urology, intensive care adult, intensive care coronary, intensive care cardiovascular surgery, and intensive care neonatal, as well as various otolaryngology diseases, such as ear, nose, and throat.

The company was incorporated in 2003 and is based in Izmir, Turkey.

Stock analysis

Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) currently trades at 4.45 TRY, while our model-based Fair Value estimate is 1.00 TRY, 77.5% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 2.34 TRY per share, and 2 of the 14 models we run sit above the 4.45 TRY price.

Bear case: the Earnings-Based group reads lowest at 0.1100 TRY, and 12 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.9400 TRY (bear) to 1.05 TRY (bull), the price of 4.45 TRY sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Nasmed Ozel Saglik Hizmetleri Ticaret AS reported revenue of 1.3B TRY in FY2025 versus 170M TRY in FY2021, a compound +67.8%/yr. Reported net income was 2.7M TRY in FY2025, compounding −37.5%/yr from FY2021.

Key figures

Market cap 2.2B TRY (≈ $44.7M) Micro · P/E ratio 234.4 · P/S ratio 0.46 · EPS (TTM) −0.1000 TRY · Net margin −3.7% · Return on equity −3.0% · Return on assets (EBIT) 2.3% · Operating margin 12.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).

What moves the price

The share trades about 78% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 18% fair-value upside, at −78%, EGEPO screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (0.0900 TRY to 15.73 TRY). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 0.9400 TRY Fair Value 1.00 TRY Bull 1.05 TRY
Price 4.45 TRY · Upside -77.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 0.9400 TRY 1.00 TRY 1.05 TRY 74
ROIC Compounder 0.9400 TRY 1.00 TRY 1.05 TRY 72
Residual Income 2.07 TRY 1.75 TRY 1.54 TRY 71
All 14 models by family
Earnings-Based
Graham-Dodd 0.0400 TRY 0.2500 TRY 0.3500 TRY 63
Lynch FV 0.0800 TRY 0.1100 TRY 0.1400 TRY 61
PEG = 1.0 0.0800 TRY 0.1100 TRY 0.1400 TRY 57
EPV 0.9400 TRY 1.00 TRY 1.05 TRY 74
Multiples
P/E Multiple 0.0900 TRY 0.1200 TRY 0.1500 TRY 63
P/S Multiple 0.0700 TRY 0.0900 TRY 0.1100 TRY 58
P/B Multiple 11.80 TRY 15.73 TRY 19.66 TRY 55
EV/EBIT 1.65 TRY 2.21 TRY 2.77 TRY 66
EV/EBITDA 4.98 TRY 6.64 TRY 8.31 TRY 67
EV/Revenue 1.17 TRY 1.68 TRY 2.20 TRY 53
Asset-Based
NCAV (Graham) 1.75 TRY 2.34 TRY 3.50 TRY 54
Economic Profit
Residual Income 2.07 TRY 1.75 TRY 1.54 TRY 71
ROIC Compounder 0.9400 TRY 1.00 TRY 1.05 TRY 72
Growth Earnings
Growth-Adj P/E 0.1100 TRY 0.1500 TRY 0.2000 TRY 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 41
Are margins and returns getting better?
Cashflow 37
Do the profits arrive as real cash?
Financial strength 66
Debt, balance sheet and risk of trouble
Investment 15
Does it invest with discipline instead of growing at any price?
Low Volatility 57
How calm the share price moves, does not count
Momentum 10
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+73.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+60.2%
What shareholders gained per year (last 5 years), in TRY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TRY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−48.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−48.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 5%

EGEPO screens overvalued: fair value 78% below the price. Compare with HCA Healthcare, Inc →

Compare Nasmed Ozel Saglik Hizmetleri Ticaret AS with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 245 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −77.5% · Bottom 25%
Profitability
Return on assets 0.1% · Bottom 25%
Net margin (12 months) −3.7% · Bottom 25%
Operating margin (12 months) 12.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) 28.1% · Top 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 234.4× · Priciest 25%
P/B 1.17× · Cheaper than median
P/S (12 months) 1.46× · Cheaper than median
EV/EBITDA 7.0× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 37
FUTURE (revenue growth)100 · sector 30
PAST (return on equity)0 · sector 32
HEALTH (low debt)100 · sector 90
DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Universal Health Services, Inc UHS $188.13 $447.22 +138% vs EGEPO
Fresenius Medical Care AG FME €40.46 €71.94 +78% vs EGEPO
Aier Eye Hospital Group 300015 ¥7.96 ¥10.86 +36% vs EGEPO
HCA Healthcare, Inc HCA $469.03 $597.68 +27% vs EGEPO
DaVita Inc DVA $183.64 $215.81 +18% vs EGEPO
Tenet Healthcare Corporation THC $268.45 $276.08 +3% vs EGEPO
Encompass Health Corporation EHC $120.47 $94.47 −22% vs EGEPO
Fresenius SE FRE €46.10 €34.56 −25% vs EGEPO
Dr. Sulaiman Al Habib Medical Services Group 4013 215.20 SAR 109.45 SAR −49% vs EGEPO
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹7,600 ₹2,908 −62% vs EGEPO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nasmed Ozel Saglik Hizmetleri Ticaret AS · Fair Value
1.00 TRY −78%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Nasmed Ozel Saglik Hizmetleri Ticaret AS Fair Value". https://www.fairvalue-calculator.com/stock/EGEPO

Frequently asked questions

Is Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) overvalued or undervalued?
As of Oct 26, 2026, our model estimates a fair value of 1.00 TRY versus a price of 4.45 TRY, about −78% upside (overvalued).
What is the fair value of EGEPO?
Our model-based fair value for Nasmed Ozel Saglik Hizmetleri Ticaret AS is 1.00 TRY (as of Oct 26, 2026), built from audited fundamentals. The current price: 4.45 TRY.
What is the quality score of EGEPO?
Nasmed Ozel Saglik Hizmetleri Ticaret AS has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
Our model-based price target is the fair value of 1.00 TRY (as of Oct 26, 2026) from 14 valuation models. Cautious scenario 0.9400 TRY, optimistic scenario 1.05 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Nasmed Ozel Saglik Hizmetleri Ticaret AS stock forecast for 2026?
Our models put fair value at 1.00 TRY, about −78% upside versus a price of 4.45 TRY (overvalued). Cautious scenario 0.9400 TRY, optimistic scenario 1.05 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
Nasmed Ozel Saglik Hizmetleri Ticaret AS reported trailing-twelve-month revenue of about 1.5B TRY (latest available figure, as of Oct 26, 2026).
What is the intrinsic value of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nasmed Ozel Saglik Hizmetleri Ticaret AS it is 1.00 TRY per share (as of Oct 26, 2026), against a price of 4.45 TRY. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Nasmed Ozel Saglik Hizmetleri Ticaret AS stock overvalued or undervalued in 2026?
As of Oct 26, 2026, EGEPO trades above its calculated fair value: price 4.45 TRY, fair value 1.00 TRY, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EGEPO?
No. The price is what the market pays today (4.45 TRY); the fair value is what the company's own numbers justify (1.00 TRY). For Nasmed Ozel Saglik Hizmetleri Ticaret AS the two are 3.45 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Nasmed Ozel Saglik Hizmetleri Ticaret AS worth?
The market values Nasmed Ozel Saglik Hizmetleri Ticaret AS at about 2.2B TRY (market capitalisation, as of Oct 26, 2026). Per share that is 4.45 TRY; our models calculate a fair value of 1.00 TRY per share.
What do the bullish and bearish scenarios say about EGEPO?
Our models span a range for Nasmed Ozel Saglik Hizmetleri Ticaret AS: cautious scenario 0.9400 TRY, base 1.00 TRY, optimistic 1.05 TRY per share (as of Oct 26, 2026, price 4.45 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EGEPO?
Nasmed Ozel Saglik Hizmetleri Ticaret AS trades at a price-to-earnings ratio of 234.4 (as of Oct 26, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.00 TRY is built from several models across several years. Other multiples: P/B 1.2, P/S 1.5, EV/EBITDA 7.0.
How solid is the balance sheet of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
Balance-sheet figures for Nasmed Ozel Saglik Hizmetleri Ticaret AS (as of Oct 26, 2026): return on equity −3.0%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is EGEPO from its 52-week high?
Nasmed Ozel Saglik Hizmetleri Ticaret AS trades at 4.45 TRY, about 78% below its 52-week high of 19.92 TRY and 2% above the low of 4.38 TRY (as of Oct 26, 2026). Distance from the high says nothing about value: that is what the fair value of 1.00 TRY is for.
Which stocks are comparable to Nasmed Ozel Saglik Hizmetleri Ticaret AS?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nasmed Ozel Saglik Hizmetleri Ticaret AS stock attractive at the current price?
The data as of Oct 26, 2026: price 4.45 TRY, calculated fair value 1.00 TRY (−78%), Quality Score 33/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EGEPO calculated?
We run Nasmed Ozel Saglik Hizmetleri Ticaret AS through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.00 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7 % above its aggregate fair value. Nasmed Ozel Saglik Hizmetleri Ticaret AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
The closing price on Oct 26, 2026 was 4.45 TRY. Our model-based fair value is 1.00 TRY, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nasmed Ozel Saglik Hizmetleri Ticaret AS right now?
The price sits above even our optimistic bull case (1.05 TRY). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (0.9400 TRY to 1.05 TRY), unusually little disagreement for a valuation.

Key figures of Nasmed Ozel Saglik Hizmetleri Ticaret AS

How large is the market capitalisation of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
The market capitalisation of Nasmed Ozel Saglik Hizmetleri Ticaret AS is 2.2B TRY (≈ $44.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
The price-to-sales ratio of Nasmed Ozel Saglik Hizmetleri Ticaret AS is 0.46 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
Earnings per share at Nasmed Ozel Saglik Hizmetleri Ticaret AS are −0.1000 TRY (price ÷ EPS = P/E 234.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
The net margin of Nasmed Ozel Saglik Hizmetleri Ticaret AS is −3.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
The return on equity (ROE) of Nasmed Ozel Saglik Hizmetleri Ticaret AS is −3.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
On an EBIT basis the return on assets of Nasmed Ozel Saglik Hizmetleri Ticaret AS is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
The operating margin of Nasmed Ozel Saglik Hizmetleri Ticaret AS is 12.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
Revenue at Nasmed Ozel Saglik Hizmetleri Ticaret AS is growing +28.1% versus a year earlier (3y avg +73.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO)?
Earnings per share at Nasmed Ozel Saglik Hizmetleri Ticaret AS are growing −64.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) generate?
The free cash flow of Nasmed Ozel Saglik Hizmetleri Ticaret AS is −37.7M TRY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) carry?
The net debt of Nasmed Ozel Saglik Hizmetleri Ticaret AS is 14.3M TRY (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Nasmed Ozel Saglik Hizmetleri Ticaret AS in the live analysis

One click puts Nasmed Ozel Saglik Hizmetleri Ticaret AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.